NCT06561906View on ClinicalTrials.gov

Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers

RecruitingOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

July 31, 2027

Study Completion Date

December 31, 2027

Conditions
Alzheimer Disease, Late OnsetMild Cognitive ImpairmentSubjective Cognitive Decline
Interventions
OTHER

Multimodal magnetic resonance imaging scanning, behavioral, genetic and plasma biomarker testing

Multimodal magnetic resonance imaging scanning, including 3DT1, 3DT2, 3DFLAIR, functional MRI, DTI, NODDI, ASL, QSM behavioral testing, such as olfaction and spatial navigation genetic testing, such as APOE, BDNF plasma biomarker testing, such as ptau, Aβ42/40、NfL、GFAP

Trial Locations (1)

210008

RECRUITING

Nanjing Drum Tower Hospital, Nanjing

All Listed Sponsors
lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER